Physician profile
Atieh S Jibbe
NPI 1811344468
$120,611.23
in general payments reported to CMS, 2019-2025
23 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $521 · 2021: $342 · 2022: $176 · 2023: $486 · 2024: $36K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $108K · Travel and Lodging: $6,542 · Food and Beverage: $3,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $108,075.00 |
| Travel and Lodging | $6,542.04 |
| Food and Beverage | $3,539.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $117,129.58 | 2024-2025 | |
| Abbvie INC. | $1,023.43 | 2019-2024 | |
| Organogenesis INC. | $516.21 | 2022-2023 | Puraply |
| Janssen Biotech, INC. | $343.91 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $214.42 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $208.08 | 2020-2025 | Otezla, Otezla |
| Celgene Corporation | $170.20 | 2019 | |
| Arcutis Biotherapeutics, INC. | $129.28 | 2025 | |
| Galderma Laboratories, L.P. | $124.87 | 2019 | |
| Janssen Scientific Affairs, LLC | $119.18 | 2019 | |
| Dermira, INC. | $117.07 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $70.22 | 2023-2024 | Sotyktu |
| Pfizer INC. | $64.81 | 2020-2022 | |
| Ucb, INC. | $58.53 | 2025 | Bimzelx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $44.14 | 2019-2020 | |
| Leo Pharma INC. | $42.76 | 2019-2021 | |
| Genzyme Corporation | $40.93 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $24.48 | 2019 | |
| Incyte Corporation | $23.44 | 2024 | Opzelura |
| Surgenex LLC | $18.02 | 2025 | Renograft, Pellograft, Surmatrix |
| Sun Pharmaceutical Industries INC. | $15.69 | 2019 | |
| Kyowa Kirin, INC. | $14.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atieh Jibbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.